Evidence map›Paper›PMID 24778468›Full record

ArticleMediators of inflammation2014

Circulating miRNA-125b is a potential biomarker predicting response to rituximab in rheumatoid arthritis.

Isabelle Duroux-Richard, Yves-Marie Pers, Sylvie Fabre, Meryem Ammari, Dominique Baeten, Guillaume Cartron, Isabelle Touitou, Christian Jorgensen, Florence Apparailly

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mediators of inflammation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Towards Personalized Medicine in Rheumatoid Arthritis.Open access rheumatology : research and reviews · 2024
    Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. MicroRNA-Based Diagnosis and Therapy.International journal of molecular sciences · 2022
    Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Isabelle Duroux-RichardInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France.
Yves-Marie PersInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.ORCID 0000-0001-5927-3773
Sylvie FabreInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Meryem AmmariInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France.
Dominique BaetenClinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.
Guillaume CartronUniversité Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Département d'Hématologie, CHU Saint Eloi, 80 Avenue Augustin Fliche, 34295 Montpellier, France ; UMR-CNRS 5235, Université Montpellier II, Place Eugène Bataillon, 34095 Montpellier, France.
Isabelle TouitouInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Unité des Maladies Autoinflammatoires, Laboratoire de Génétique, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Christian JorgensenInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Florence ApparaillyInserm U844, CHU Saint Eloi, Bâtiment INM, 80 Avenue Augustin Fliche, 34295 Montpellier Cedex 5, France ; Université Montpellier I, UFR de Médecine, Boulevard Henri IV, 34090 Montpellier, France ; Clinical Department for Osteoarticular Diseases, CHU Lapeyronie, Avenue Gaston Giraud, 34295 Montpellier, France.
Inserm · FRAmsterdam UMC Location University of Amsterdam · NLCentre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although biologic therapies have changed the course of rheumatoid arthritis (RA), today's major challenge remains to identify biomarkers to target treatments to selected patient groups. Circulating micro(mi)RNAs represent a novel class of molecular biomarkers whose expression is altered in RA. Our study aimed at quantifying miR-125b in blood and serum samples from RA patients, comparing healthy controls and patients with other forms of rheumatic diseases and arthritis, and evaluating its predictive value as biomarker for response to rituximab. Detectable levels of miR-125b were measured in total blood and serum samples and were significantly elevated in RA patients compared to osteoarthritic and healthy donors. The increase was however also found in patients with other forms of chronic inflammatory arthritis. Importantly, high serum levels of miR-125b at disease flare were associated with good clinical response to treatment with rituximab three months later (P = 0.002). This predictive value was not limited to RA as it was also found in patients with B lymphomas. Our results identify circulating miR-125b as a novel miRNA over expressed in RA and suggest that serum level of miR-125b is potential predictive biomarker of response to rituximab treatment.

Indexed as

AgedAntibodies, Monoclonal, Murine-DerivedAntirheumatic AgentsArthritis, RheumatoidBiomarkersChronic DiseaseFemaleGene Expression RegulationHumansInflammationMaleMicroRNAsMiddle AgedPredictive Value of TestsRituximabTreatment OutcomeAntibodies, Monoclonal, Murine-DerivedAntirheumatic AgentsBiomarkersMicroRNAsMIRN125 microRNA, humanRituximab

Identifiers

PMID24778468
PMCPMC3980876
OpenAlexW2088853673

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.